A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

The trial is an open label extension study. Eligible patients from the RPC01-201, RPC01-301,
and RPC01-1001 trials diagnosed with relapsing Multiple Sclerosis (RMS) will be enrolled to
receive study drug until the end of the trial or until the Sponsor discontinues the
development program.

Eligibility Criteria:

- Completed one of the parent trials: RPC01-201, RPC01-301 or RPC01-1001

- Does not have a condition that would require withdrawal from one of the parent trials
(RPC01-201, RPC01-301, RPC01-1001)

- Has no conditions requiring treatment with a prohibited medication

- Ability to provide written informed consent and to be compliant with the schedule of
protocol assessments

- Patients of reproduction potential (males and females) must practice an acceptable
method of birth control